Silence Therapeutics plc, AIM: SLN a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, has told DirectorsTalk that on 18 April 2016 it received notification that, on the same day, the following purchases of ordinary shares in the Company were made:
Ali Mortazavi, Chief Executive of the Company, purchased 160,000 Ordinary Shares at a price of 125.00 pence per Ordinary Share.
Stephen Parker, Chairman of the Company, purchased 6,478 Ordinary Shares at a price of 123.31p per Ordinary Share.
Following the above purchases, Ali Mortazavi holds a beneficial interest in 1,937,399 Ordinary Shares, representing 2.78% of the Company’s issued share capital. Stephen Parker holds 6,478 Ordinary Shares, representing 0.01% of the Company’s issued share capital